Chronic Heart Failure Research

Heart failure is a chronic, progressive condition in which the heart muscle is unable to pump enough blood through to meet the body 's needs for blood and oxygen. Basically, the heart can 't keep up with its workload. American Heart Association Statistics (2016) reveals that heart failure accounts for 36% of cardiovascular disease deaths. Projections report a 46% increase in the prevalence of Heart Failure (HF) by 2030 by affecting over 8 million people above 18 years with the disease. Healthy People 2020 goals are focused on attaining high quality longer lives free of preventable diseases, promotion of quality of life, healthy development and healthy behaviors across all stages of life (Healthy People 2020, 2015).

6. What laboratory tests should be ordered for M.G. related to the order for furosemide (Lasix)? (Select all that apply)

Evaluation is the final and often the most critical step in evidence based research and practice. Evaluation of evidence based practice follows a pathway beginning with the selection of the area for improvement, synthesizing the research into a process improvement activity and evaluating both the implementation of the process improvement as well and the outcomes of the intervention (Titler, 2008). To measure the results of process change in the management of heart failure patients a retrospective analysis will be conducted comparing the readmission rates of a pilot and control population over a 6-month period. The pilot population will be evaluated with the LACE index readmission risk assessment upon admission and subsequently receive the recommended interventions based on the risk stratification. In comparison, the control group will receive the current process of telephonic contact only. The pilot group will include patients over the age of 18 residing in zip-codes 45402 and 45403,

CHF stands for congestive heart failure. There are several types of congestive heart failure. There is left sided heart failure which may cause fluid to back up into your lungs which will cause shortness of breath. Right sided heart failure may cause fluid to back up into your abdomen, and other body parts. Systolic heart failure causes the left ventricle can’t contract vigorously, which causes problems with the heart pumping blood. The final type is diastolic heart failure means the left ventricle can’t relax or fill up adequately.

Therapeutic measures for a patient with congestive heart failure would be daily weights, dietary sodium restrictions, positioning in high or semi-Fowler’s position, frequent vital signs, oxygen by cannula or mask, medical devices: pacemakers, internal cardiac defibrillator, biventricular cardiac pacemaker, ventricular assist device, medications: digoxin, diuretics, inotropes, nesiritide, beta blockers, surgery: heart valve repair or replacement, coronary

In patients with symptomatic chronic HF who do not tolerate ACE inhibitors, angiotensin II type I receptor blockers (ARBs) can be used as an alternative to improve morbidity and mortality. However, the higher rate of hypotension, renal dysfunction, and hyperkalaemia with such a combination therapy warrants close monitoring of these parameters. As patients with end stage heart failure frequently show signs of fluid retention or have a history of such, inhibitors of the renin-angiotensin system should be co-administered with diuretics most commonly loop diuretics, which usually leads to rapid symptomatic improvement of dyspnea and exercise tolerance while lacking significant effects on survival. In addition to standard treatment with ACE inhibitors and diuretics, patients with symptomatic stable systolic heart failure should be treated with b-adrenergic receptor blockers unless there are contraindications. Additionally aldosterone receptor antagonists are recommended in addition to ACE inhibitors, b-adrenergic receptor blockers, and diuretics, unless contraindicated.

management have been shown to help reduce the number of readmissions with the key topic being the education of the patient (Hobbs et al., 2016). In designing this program to reduce the readmission for the heart failure patient a review of the literature was completed and follows.

After the occurrence of a heart attack, patients are typically put on pharmacological agents to help improve the heart’s now compromised condition and prevent the occurrence of another infarction. The two main categories of drugs used for this purpose are ACE inhibitors and ß- blockers. As previously stated, ACE is an enzyme that converts angiotensin I into angiotensin II. This can be problematic in the failing heart because of the effects of angiotensin II, specifically vasoconstriction and enhanced sympathetic activity (Jackson, et al., 2000). By inhibiting this enzyme, the constricted blood vessels are relaxed and blood pressure is lowered. This allows the heart to return to pumping

Coronary heart disease (CHD) and chronic heart failure (CHF) are a major public health concern in the world; each year both of them causes huge number of direct and indirect economic losses for many developed and developing countries, which is the ultimate outcome of disease progression in all patients with cardiovascular disease, is even greater for medical and public investments in patients with heart failure. In the United States every 1000 people over the age of 65 in 10 patients with chronic heart failure, Projections show that by 2030, the total cost of HF will increase almost 127% to $69.7 billion for every US adult. The costs associated with treating HF comorbidities and HF exacerbations in youths are significant, totaling nearly $1 billion in inpatient costs, and may be rising [8]. Even today's progress in medical technology and the development of medicine, the prognosis of patients with heart failure variability is more serious. Therefore, it is extremely important to classify the risk stratification accurately and to distinguish the high-risk population and start

s your topic based on patient education and medication compliance in heart failure patients to improve their condition? Also, what type of research method was used for each of the sources, is it quantitative or qualitative? The difference between the two is that “quantitative studies is between experimental research, in which researchers actively intervene, and nonexperimental research in which researchers make observations of existing phenomena without intervening” (Beck & Polit, 2012, p. 69). I think this topic is an important and interesting one because many of the patients I come across have heart failure. I would be interested to see what types of interventions were used in the studies to increase compliance and how this was measured.

Researchers at the Cardiovascular Research Center at Icahn School of Medicine have successfully tested a powerful gene therapy known as “SUMO-1” that is delivered directly into the myocardium to reverse heart failure in large animal models. Although this treatment has yet to be proven in human clinical trials, it may be one of the first treatments that can actually shrink hypertrophied myocardium tissue; thereby significantly improving the damaged heart’s life-sustaining function.

A journey with heart failure has been a difficult one. It started out a few years ago when I turned 66 years ago. It started with what seemed like a bad flu. I went to go see my doctor and he told me that there was a bad flu going around that that I just need to ride it out and give it time to go away. After a few weeks, my breathing got worse so I went back to see it and he ran some tests and told me I had heart failure and not a flu. He gave me some medications that make me go to the bathroom very often and that helped me breathe better. He explained that my heart was weak and that I had extra fluid in my body and that is why my feet were swollen and I was having trouble breathing. The water pills have helped me

Heart failure affects about 5.7 million adults in the United States and costs an estimated $30.7 billion every year. This condition occurs when the heart is unable to pump enough blood and oxygen to the body. A majority of patients can be treated using pharmacologic options, restricting sodium intake, and increasing daily physical activity. ¬1 However, a select group of patients will advance to a stage of heart failure where the heart can no longer pump adequate blood to fulfill their body’s requirements. These patients may benefit from an LVAD (left ventricular assist device) implant surgery. An LVAD is a surgically implanted mechanical pump which is attached to the heart. An LVAD functions by moving blood from the left ventricle to the aorta

Heart failure is a debilitating condition, affecting around 1-2% of the UK population (Sutherland, 2010). Its prevalence is rising due to an increase in its risk factors, most notably an increased population life expectancy (Patient.co.uk, 2014). In the scenario Mr Williams is an obese 65-year-old man, exhibiting numerous symptoms indicative of congestive heart failure. In this PBL write-up, I aim to explore the issues raised, whilst relating them to the pathophysiology of heart failure.

Patient situation: Mrs. Smith, a seventy-six year old patient was admitted with a diagnosis of congestive heart failure (CHF). Now she is stabilized after seven days of treatment and ready to be discharged. Patient is recommended to be on 1200 ml fluid restriction per day to manage her condition at home.